These results indicate that loss of BRM sensitizes cells to cisplatin only if GTF2H1 protein levels are lowered, and imply that GTF2H1 levels could be used as a predictive marker for platinum drug sensitivity of SWI/SNF-deficient cancers. Here, GTF2H1 is linked to cancer.